| 1) |
Black DM, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41. |
| 2) |
Cummings SR, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82. |
| 3) |
Ettinger B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45. |
| 4) |
Harris ST, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52. |
| 5) |
Chesnut CH, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76. |
| 6) |
Alexandersen P, et al. Iprifravone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482-8. |
| 7) |
Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. |
| 8) |
Lindsay R, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3. |
| 9) |
Center JR, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82. |
| 10) |
Kado DM, et al. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med 1999;159:1215-20. |
| 11) |
Cauley JA, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the heart and estrogen/progestin replacement study (HERS). Am J Med 2001;110:442-50. |
| 12) |
McClung MR, et al. Effect of risedronate on the risk of hip fracture in elderly women. 2001;344:333-40. |
| 13) |
Kannus P, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000;343:1506-13. |